305 related articles for article (PubMed ID: 24324105)
1. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
[TBL] [Abstract][Full Text] [Related]
2. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
Okabe K; Beppu T; Haraoka K; Oh-Uchida Y; Yamamura S; Tomiyasu S; Yamanaka T; Sano O; Masuda T; Chikamoto A; Fujiyama S; Baba H
Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
[TBL] [Abstract][Full Text] [Related]
3. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
Imai N; Ikeda K; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Jpn J Clin Oncol; 2012 Mar; 42(3):175-82. PubMed ID: 22210921
[TBL] [Abstract][Full Text] [Related]
4. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
[TBL] [Abstract][Full Text] [Related]
5. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
Tawada A; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Ogasawara S; Suzuki E; Kanai F; Yoshikawa M; Yokosuka O
Anticancer Res; 2015 Jan; 35(1):549-54. PubMed ID: 25550601
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
Matsumoto T; Ichikawa H; Imai J; Hayashi T; Tomita K; Mine T; Kojima S; Watanabe N; Hasebe T
Anticancer Res; 2017 Jun; 37(6):3183-3187. PubMed ID: 28551662
[TBL] [Abstract][Full Text] [Related]
7. Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.
Oguro S; Hashimoto S; Tanaka T; Inoue M; Nakatsuka S; Kuribayashi S; Asakura K; Kawachi S; Tanabe M; Kitagawa Y; Ebinuma H; Saito H; Hibi T
Jpn J Radiol; 2012 Nov; 30(9):735-42. PubMed ID: 22923183
[TBL] [Abstract][Full Text] [Related]
8. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
Shirono T; Iwamoto H; Niizeki T; Shimose S; Nakano M; Satani M; Okamura S; Noda Y; Kamachi N; Kuromatsu R; Sakai M; Nomiyama M; Kuwano T; Tanaka M; Koga H; Torimura T
Oncology; 2019; 96(2):79-86. PubMed ID: 30293080
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Imai Y; Chikayama T; Nakazawa M; Watanabe K; Ando S; Mizuno Y; Yoshino K; Sugawara K; Hamaoka K; Fujimori K; Inao M; Nakayama N; Oka M; Nagoshi S; Mochida S
J Gastroenterol; 2012 Feb; 47(2):179-86. PubMed ID: 21976133
[TBL] [Abstract][Full Text] [Related]
10. Warming effect on miriplatin-lipiodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma: preliminary clinical experience.
Kora S; Urakawa H; Mitsufuji T; Osame A; Higashihara H; Yoshimitsu K
Cardiovasc Intervent Radiol; 2013 Aug; 36(4):1023-9. PubMed ID: 23238851
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of transcatheter arterial chemolipiodolization of miriplatin for multiple hepatocellular carcinoma].
Arai H; Kobayashi T; Izuka K; Ueno T; Mori K; Takizawa D; Toyoda M; Takayama H; Abe T
Gan To Kagaku Ryoho; 2012 Dec; 39(13):2513-6. PubMed ID: 23235170
[TBL] [Abstract][Full Text] [Related]
12. Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma.
Nishikawa H; Osaki Y; Kita R; Kimura T; Ohara Y; Takeda H; Sakamoto A; Saito S; Nishijima N; Nasu A; Komekado H; Nishiguchi S
Oncol Rep; 2014 Jan; 31(1):65-72. PubMed ID: 24220763
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of a monodisperse solid-in-oil-in-water miriplatin/ lipiodol emulsion in transcatheter arterial chemoembolization using a rabbit VX2 tumor model.
Yasui D; Yamane A; Itoh H; Kobayashi M; Kumita SI
PLoS One; 2020; 15(8):e0222553. PubMed ID: 32756561
[TBL] [Abstract][Full Text] [Related]
14. Initial safety and outcomes of miriplatin plus low-dose epirubicin for transarterial chemoembolisation of hepatocellular carcinoma.
Iwazawa J; Hashimoto N; Ohue S; Mitani T
Anticancer Res; 2012 Nov; 32(11):5039-44. PubMed ID: 23155276
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for the leakage of chemotherapeutic agents into systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma.
Hsieh MY; Lin ZY; Chen SH; Chuang WL
Kaohsiung J Med Sci; 2011 Oct; 27(10):431-6. PubMed ID: 21943814
[TBL] [Abstract][Full Text] [Related]
16. A transcatheter arterial chemotherapy using a novel lipophilic platinum derivative (miriplatin) for patients with small and multiple hepatocellular carcinomas.
Yukisawa S; Ishii H; Kasuga A; Matsuyama M; Kuraoka K; Takano K; Ozaka M
Eur J Gastroenterol Hepatol; 2012 May; 24(5):583-8. PubMed ID: 22330234
[TBL] [Abstract][Full Text] [Related]
17. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
[TBL] [Abstract][Full Text] [Related]
18. Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model.
Xia X; Li X; Feng G; Zheng C; Liang H; Zhou G
Acta Radiol; 2013 Jul; 54(6):684-9. PubMed ID: 23507934
[TBL] [Abstract][Full Text] [Related]
19. Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC.
Koizumi Y; Hirooka M; Uehara T; Kisaka Y; Uesugi K; Kumagi T; Abe M; Matsuura B; Hiasa Y; Onji M
Hepatogastroenterology; 2011; 58(106):512-5. PubMed ID: 21661422
[TBL] [Abstract][Full Text] [Related]
20. Transcatheter intraarterial perfusion: MR monitoring of chemoembolization for hepatocellular carcinoma--feasibility of initial clinical translation.
Larson AC; Wang D; Atassi B; Sato KT; Ryu RK; Lewandowski RJ; Nemcek AA; Mulcahy MF; Kulik LM; Miller FH; Salem R; Omary RA
Radiology; 2008 Mar; 246(3):964-71. PubMed ID: 18309018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]